HM Payson & Co’s Oncolytics Biotech ONCY Stock Holding History

HM Payson & Co’s Portfolio ONCY Stock Details ONCY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-28	Closed	-$38	–	991
2023 Q4	$38	Buy	+28	New	+$44	﹤0.01%	960

Other funds holding ONCY

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

CIBC World Market Toronto, Ontario, Canada $61.3B AUM 39.33% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HM Payson & Co's ONCY Position: Q1 2024 in Review

HM Payson & Co sold out of Oncolytics Biotech (ONCY) in Q1 2024, closing a stake of 28 shares — an estimated $38 sold.

HM Payson & Co first reported a position in ONCY in Q4 2023 and held it in 1 quarter. The position peaked at $38 in Q4 2023. 36 funds tracked by Wall St. Rank hold ONCY as of Q1 2024.

HM Payson & Co reported no remaining Oncolytics Biotech position as of Q1 2024 after selling out during the quarter.
HM Payson & Co sold 28 Oncolytics Biotech shares in Q1 2024, an estimated $38.
HM Payson & Co first reported a position in Oncolytics Biotech in Q4 2023 and held it in 1 quarter.
HM Payson & Co's Oncolytics Biotech position peaked at $38 in Q4 2023.
36 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q1 2024.

Based on HM Payson & Co's 13F filing for Q1 2024, filed 20 Jun 2024.